Search Results 701-710 of 16678 for Trazodone

  1. Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer - Mayo Clinic

    Taselisib is a PI3K inhibitor. The PI3K pathway is involved is cancer growth. Androgen may cause the growth of tumor cells. Enzalutamide may stop the growth of ...

  2. A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RO7303509 in Participants With Systemic Sclerosis - Mayo Clinic

    The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of 12 weeks of RO7303509 treatment in patients with systemic sclerosis ( ...

  3. A Study Using a Combined Lung and Heart Point of care ultrasound (POCUS) Examination to Estimate Cardiac Filling Pressures in Hospitalized Patients - Mayo Clinic

    The purpose of this study is to implement a rapid hemodynamic heart-lung protocol performed at the bedside by cardiology and critical care fellows and ...

  4. Octreotide (oral route) - Side effects & dosage - Mayo Clinic

    Octreotide is used for the long-term treatment of acromegaly (a growth hormone disorder) in patients who have been previously treated with octreotide or ...

  5. A Study to Evaluate Safety of Enapotamab Vedotin in Patients with Solid Tumors - Mayo Clinic

    About this study. The purpose of the trial is to establish the tolerability of HuMax-AXL-ADC in a mixed population of patients with specified solid tumors.

  7. Neurology - Clinical trials

    The purpose of this study is to follow patients with REM sleep behavior disorder (RBD) over time and learn which types of RBD patients may be at risk of ...

  8. Donor-Specific Cell Free DNA Monitoring of Thoracic Allografts - Mayo Clinic

    The purpose of this study is to determine if DNA originating from the transplanted heart or lung can be detected in the blood and used to monitor for rejection.

  9. Midostaurin (oral route) - Side effects & dosage - Mayo Clinic

    For treatment of acute myeloid leukemia: Adults—50 milligrams (mg) 2 times a day on Days 8 to 21 of each cycle of induction with cytarabine and daunorubicin, ...

  10. A Phase I Study of TAS-102 in Patients with Advanced Solid Tumors with Renal Impairment - Mayo Clinic

    Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...